CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00270907
Recruitment Status : Completed
First Posted : December 29, 2005
Last Update Posted : February 13, 2013
CTI BioPharma
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
The goal of this phase I clinical study is to find the highest safe dose of gemcitabine and CT-2103 that can be given in combination for the treatment of metastatic breast cancer. The safety and effectiveness of this combination will also be studied. This clinical trial will be offered to patients who are being considered for treatment with gemcitabine. Research lab samples and research biopsies will not be requested as part of this study.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Breast Cancer Drug: CT-2103 Drug: Gemcitabine Phase 1

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer
Study Start Date : December 2005
Actual Primary Completion Date : October 2012
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: CT-2103 + Gemcitabine
CT-2103 135 mg/m^2 intravenous (IV) on Day 1. Gemcitabine 1000 mg/m^2 IV on Day 1 and 8.
Drug: CT-2103
135 mg/m^2 IV on Day 1.
Other Name: Xyotax

Drug: Gemcitabine
1000 mg/m^2 IV on Day 1 and 8.
Other Name: Gemzar

Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) of CT-2103 [ Time Frame: 21 days ]
    MTD defined as the level of CT-2103 at which 2 out of 6 patients had dose limiting toxicity (DLT) where the primary DLT events of CT-2103 are uncomplicated neutropenia, febrile neutropenia, and/or grade 3 neuropathy. Assessments during the first cycle of therapy, where cycle is 21 days.

Secondary Outcome Measures :
  1. Number of Participants with Response [ Time Frame: 6 weeks following chemotherapy ]
    Evaluation of response in participants with measurable disease after each 6 weeks of chemotherapy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.
  2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.
  3. Previous taxane therapy is allowed.
  4. Age >/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.
  5. Eastern Cooperative Oncology Group (ECOG) performance status </= 2 (Karnofsky >/= 60%).
  6. Measurable disease is not required.
  7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.
  8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.
  9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.
  10. Patients must have normal organ and marrow function as defined below: leukocytes >/= 3,000/ul; absolute neutrophil count >/= 1,500/ul; platelets >/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) </= 2.5 * institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance >/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).
  11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.

Exclusion Criteria:

  1. Patients with preexisting neuropathy >/= grade 2.
  2. Patients may not be receiving any other investigational agents.
  3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.
  5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.
  7. Previous history of stem cell transplantation.
  8. History of central nervous system metastases.
  9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00270907

United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
CTI BioPharma
Principal Investigator: Marjorie Green, MD M.D. Anderson Cancer Center

Additional Information:
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT00270907     History of Changes
Other Study ID Numbers: 2005-0133
First Posted: December 29, 2005    Key Record Dates
Last Update Posted: February 13, 2013
Last Verified: February 2013

Keywords provided by M.D. Anderson Cancer Center:
Metastatic Breast Cancer
Breast Cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators